Tag: APERTO
Aperto® DCB: A breakthrough in prolonging dialysis access survival
This advertorial is sponsored by Cardionovum.
Cardionovum’s CE-marked Aperto drug-coated balloon (DCB) is, according to expert opinion and a growing evidence base, spearheading a revolution...
DCBs are “first-line treatment for better outcomes” for typical vascular access...
NOTE: This video is ONLY available to watch in selected countries and geographies
Could drug-coated balloons (DCBs) be “the perfect device” for the treatment...
The Aperto® drug-coated balloon: A “first-line” treatment for arteriovenous fistula lesions
This advertorial is sponsored by Cardionovum®.
In 2023, there are a number of different options available for treating the vascular access complications of thrombosis and...
APERTO DCB a “very promising new technology” for central vein stenosis
NOTE: This video is ONLY available to watch in selected countries and geographies
“Patients who are on chronic dialysis really depend on arteriovenous (AV)...
Aperto® drug-coated balloon technology shows promise in dialysis access patients
This advertorial is sponsored by Cardionovum®.
The Aperto drug-coated balloon (DCB) technology (Cardionovum) is “one of the very promising new technologies” for treating central vein stenosis...
APERTO becomes the first drug-coated balloon to be approved in China...
APERTO, Cardionovum’s paclitaxel-coated balloon for arterio-venous access, has received market approval for China, making it the first high pressure drug-coated balloon (DCB) available in...
Registry shows better patency and fewer reinterventions for Aperto drug-coated balloon...
Drug-coated balloon treatment for vascular access stenosis offers a real alternative to plain balloon angioplasty, reducing the rate of reinterventions and prolonging the lifespan of...
